LecT-Hepa, a glyco-marker derived from multiple lectins, as a predictor of liver fibrosis in chronic hepatitis C patients.

Abstract

UNLABELLED:

Assessment of liver fibrosis in patients with chronic hepatitis C (CHC) is critical for predicting disease progression and determining future antiviral therapy. LecT-Hepa, a new glyco-marker derived from fibrosis-related glyco-alteration of serum alpha 1-acid glycoprotein, was used to differentiate cirrhosis from chronic hepatitis in a single-center study. Herein, we aimed to validate this new glyco-marker for estimating liver fibrosis in a multicenter study. Overall, 183 CHC patients were recruited from 5 liver centers. The parameters Aspergillus oryzae lectin (AOL) / Dature stramonium lectin (DSA) and Maackia amurensis lectin (MAL)/DSA were measured using a bedside clinical chemistry analyzer in order to calculate LecT-Hepa levels. The data were compared with those of seven other noninvasive biochemical markers and tests (hyaluronic acid, tissue inhibitor of metalloproteases-1, platelet count, aspartate aminotransferase-to-platelet ratio index [APRI], Forns index, Fib-4 index, and Zeng's score) for assessing liver fibrosis using the receiver-operating characteristic curve. LecT-Hepa correlated well with the fibrosis stage as determined by liver biopsy. The area under the curve (AUC), sensitivity, and specificity of LecT-Hepa were 0.802, 59.6%, and 89.9%, respectively, for significant fibrosis; 0.882, 83.3%, and 80.0%, respectively, for severe fibrosis; and 0.929, 84.6%, and 88.5%, respectively, for cirrhosis. AUC scores of LecT-Hepa at each fibrosis stage were greater than those of the seven aforementioned noninvasive tests and markers.

CONCLUSION:

The efficacy of LecT-Hepa, a glyco-marker developed using glycoproteomics, for estimating liver fibrosis was demonstrated in a multicenter study. LecT-Hepa given by a combination of the two glyco-parameters is a reliable method for determining the fibrosis stage and is a potential substitute for liver biopsy.

• Authors: Kiyoaki Ito, Atsushi Kuno, Yuzuru Ikehara, Masaya Sugiyama, Hiroaki Saito, Yoshihiko Aoki, Teppei Matsui, Masatoshi Imamura, Masaaki Korenaga, Kazumoto Murata, Naohiko Masaki, Yasuhito Tanaka, Shuhei Hige, Namiki Izumi, Masayuki Kurosaki, Shuhei Nishiguchi, Michiie Sakamoto, Masayoshi Kage, Hisashi Narimatsu, Masashi Mizokami
• Journal: Hepatology (Baltimore, Md.) (Hepatology) Vol. 56 Issue 4 Pg. 1448-56 (Oct 2012) ISSN: 1527-3350 [Electronic] United States
• PMID: 22535703 (Publication Type: Comparative Study, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2012 American Association for the Study of Liver Diseases.

Chemical References

• Biomarkers
• Glycoproteins
• Intercellular Signaling Peptides and Proteins
• Lectins
• Membrane Proteins
• Orosomucoid
• CNMD protein, human
• Aspartate Aminotransferases

Topics

• Age Factors
• Aged
• Analysis of Variance
• Aspartate Aminotransferases (blood)
• Biomarkers (blood)
• Cohort Studies
• Confidence Intervals
• Disease Progression
• Female
• Glycoproteins (blood)
• Hepatitis C, Chronic (blood)
• Humans
• Intercellular Signaling Peptides and Proteins (metabolism)
• Lectins (blood)
• Liver Cirrhosis (blood, virology)
• Liver Function Tests
• Logistic Models
• Male
• Membrane Proteins (metabolism)
• Middle Aged
• Multivariate Analysis
• Orosomucoid
• Predictive Value of Tests
• Prognosis
• Prospective Studies
• ROC Curve
• Risk Assessment
• Severity of Illness Index
• Sex Factors
• Statistics, Nonparametric